Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04271956 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of Zanubrutinib Plus Tislelizumab Treatment With or Without Sonrotoclax for Patients With Richter Transformation

Study acronym: CLL-RT1
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 11 months later Aug 2026 → Aug 2027
See other at-risk trials from German CLL Study Group

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Aug 2026 to Aug 2027v13
  2. Site details revised at 1 of 11 sitesv12
  3. Trial status: Active, Not Recruiting to Recruitingv11 Show 8 more changesShow less
    • Primary completion date: Dec 2023 to Aug 2026
    • Enrollment target: 57 to 83
    • Study sites: 12 to 11
    • Study completion date: Dec 2024 to Aug 2026
    • Interventions: Tislelizumab (Biological), Zanubrutinib (Drug) to Sonrotoclax (Drug), Tislelizumab (Biological), Zanubrutinib (Drug)
    • Eligibility criteria expanded, about 322 words
    • Study arms: 1 to 2
    • Study title expanded, about 3 words
  4. Primary completion date: May 2023 to Dec 2023
    • Study completion date: Dec 2023 to Dec 2024
    v10
  5. Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date: Feb 2023 to May 2023
    • Site details revised at 12 of 12 sites
    v9
Show 7 earlier versionsHide 7 earlier versions
  1. Enrollment target: 48 to 57
    • Primary completion date: Aug 2022 to Feb 2023
    • Study completion date: Jun 2023 to Dec 2023
    v8
  2. 2 versions Re-verified since Feb 4, 2021, no change to tracked fieldsv6-v7
  3. Site details revised at 1 of 12 sitesv5
  4. Site details revised at 2 of 12 sitesv4
  5. Study sites: 1 to 12v3
  6. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Mar 2020 to Feb 19, 2020
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of the CLL-RT1 trial is to evaluate the efficacy and safety of zanubrutinib (BGB-3111), a BTK inhibitor plus tislelizumab (BGB-A317), a PD1 inhibitor for treatment of patients with Richter Transformation
Trial Details
NCT Number NCT04271956
Lead Sponsor German CLL Study Group
Conditions
(from sponsor)		 Richter Transformation
Enrollment 83 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov